Recent Updates
Recently added Catalysts
MRVI Negative Sentiment Score: 20/100

Maravai LifeSciences Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 5, 2025 to Discuss Your Rights – MRVI

Key Takeaway: Maravai LifeSciences Holdings, Inc. is facing a class action securities lawsuit filed by Levi & Korsinsky, LLP. The lawsuit claims that the company engaged in securities fraud between August 2024 and February 2025, citing issues such as inadequate financial reporting controls and material misstatements regarding revenue recognition and goodwill. Investors affected by this alleged fraud are encouraged to participate in the lawsuit, with a deadline to request lead plaintiff status set for May 5, 2025. Levi & Korsinsky has a strong track record in securities litigation, with no cost required for class members to participate.

Market Sentiment Analysis

CONCERNS & RISKS

  • Maravai LifeSciences faces a class action lawsuit for alleged securities fraud.
  • The complaint alleges that the company had inadequate controls over financial reporting.
  • False statements were made regarding the company’s revenue recognition and goodwill.

Full Press Release Details

NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:
MRVI investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4)as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Maravai LifeSciences during the relevant time frame, you have until May 5, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What lawsuit involves Maravai LifeSciences?

A class action securities lawsuit has been filed against Maravai LifeSciences.

What is the timeline for the lawsuit?

The lawsuit covers the period from August 7, 2024, to February 24, 2025.

Who can join the class action lawsuit?

Investors who suffered losses in Maravai during the specified timeframe can join.

What are the alleged issues in the lawsuit?

The lawsuit alleges false statements and inadequate financial controls by the company.

Is there a cost to participate in the lawsuit?

There is no cost to participate for class members seeking compensation.

Last updated: Mar 24, 2025